STOCK TITAN

Viking Therapeutics (VKTX) Stock News

VKTX NASDAQ

Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.

Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX) presented an exploratory analysis showing BMI-category improvement in 74% of participants receiving weekly injectable VK2735.

In the Phase 2 VENTURE analysis, 74% improved by at least one body mass index (BMI) category after 13 weeks, versus 15% receiving placebo. No VK2735-treated participant moved to a higher BMI category. Participants whose category improved had larger reductions in several cardiometabolic measures than treated participants whose category did not change. Previously reported results showed mean weight reductions of up to 14.7% from baseline; 92% of drug-related treatment-emergent adverse events were mild or moderate.

A second ObesityWeek poster described baseline characteristics in the ongoing Phase 3 VANQUISH-2 trial. Viking expects the VANQUISH studies, which assess weekly injections over 78 weeks, to finish in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.28%
Tags
-
Rhea-AI Summary

Viking Therapeutics (VKTX) will present two VK2735 posters at ObesityWeek, taking place November 14–17, 2026, in Washington, D.C.

The November 14 poster covers baseline characteristics from the Phase 3 VANQUISH-2 trial in adults with overweight and type 2 diabetes. The November 15 poster addresses obesity severity and cardiometabolic parameters in the Phase 2 VENTURE study. Both concern subcutaneous VK2735.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.01%
Tags
none
-
Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX) will participate in five investor conferences in November and December 2026, with management attending investor meetings.

Fireside chats are scheduled for November 11 at Stifel in New York, November 17 at UBS in London, November 18 at Jefferies in London, and December 2 at Piper Sandler in New York. Management will also attend investor meetings at Truist in New York on November 12. Live webcasts and subsequent replays of the Jefferies and Piper Sandler chats will be available through Viking’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
conferences
Rhea-AI Summary

Viking Therapeutics (VKTX) initiated Phase 3 trials of oral obesity treatment VK2735 while advancing its injectable program and maintenance-dosing studies. The oral SUNRISE trials will evaluate daily treatment for 68 weeks, targeting 560 adults each. Viking expects the injectable VANQUISH trials to finish in 2027, with extension studies beginning in the first quarter of 2027 and extension results anticipated in 2028.

In Part 1 of the maintenance study, every-other-week dosing retained 83%–97% of initial weight loss at Week 33; monthly dosing retained 82%–90%, versus 61% for placebo. Part 2 has begun, with results expected in 2027. The VK3019 Phase 1 single-dose study is nearing completion. Quarter-end cash was $960 million following concurrent public offerings of common stock and convertible senior notes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
-
Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX) will release its third-quarter 2026 financial results after the market close on October 28, 2026. The company will host a conference call at 4:30 p.m. Eastern Time that day to discuss the results and general corporate updates. A telephone replay will be available until November 4, 2026, and a webcast archive will remain available on the company’s website for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
earnings date
-
Rhea-AI Summary

Viking Therapeutics (VKTX) has initiated its SUNRISE Phase 3 clinical program to evaluate oral VK2735 for obesity. SUNRISE-1 and SUNRISE-2 each target 560 adults, without and with type 2 diabetes, respectively. The placebo-controlled trials will assess once-daily treatment over 68 weeks, with percent change in body weight from baseline as the primary endpoint.

The Phase 2 VENTURE-Oral study achieved its primary and secondary endpoints. Mean body weight reductions reached up to 12.2% after 13 weeks; 98% of reported drug-related adverse events arising during treatment were mild or moderate. Gastrointestinal events were the most common. Viking is also conducting an oral maintenance dosing trial. Its injectable Phase 3 VANQUISH-1 and VANQUISH-2 studies are fully enrolled, with approximately 4,500 and 1,000 adults, respectively, evaluating weekly treatment over 78 weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.43%
Tags
Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX) initiated an exploratory trial testing oral and additional injectable VK2735 maintenance regimens in adults with obesity. Part 2 of a maintenance study begun in 2025 is a randomized, double-blind, placebo-controlled trial in approximately 195 otherwise healthy adults with obesity. Participants will receive weekly subcutaneous injections of VK2735 or placebo for 21 weeks, then transition to daily or weekly oral doses, monthly or every-other-week injections, or placebo through Week 33.

The study will evaluate safety, tolerability and pharmacokinetics, meaning how the drug moves through the body, with exploratory weight-change endpoints. Viking expects to report Part 2 results in 2027. Its ongoing Phase 3 VANQUISH-1 and VANQUISH-2 trials are fully enrolled with approximately 4,500 and 1,000 adults, respectively, and evaluate weekly injectable VK2735 for 78 weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
-
Rhea-AI Summary

Viking Therapeutics (VKTX) closed concurrent upsized stock and convertible-note offerings, generating approximately $575.0 million in gross proceeds. The offerings comprised 9,035,714 common shares at $35.00 each and $258.75 million in 2.00% convertible senior notes due 2032. Those amounts include the underwriters’ full exercise of options to purchase 1,178,571 additional shares and $33.75 million in additional note principal.

Viking estimates net proceeds of approximately $547.8 million after underwriting discounts, commissions and estimated offering expenses. The company intends to use the proceeds for its VK2735 and VK3019 programs, other research and development, working capital and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
-
Rhea-AI Summary

Viking Therapeutics (VKTX) priced concurrent stock and convertible-note offerings totaling $500 million on September 24, 2026. The stock offering covers 7,857,143 shares at $35.00 each; the note offering comprises $225.0 million of 2.00% senior unsecured notes due October 15, 2032. Each offering was upsized from $200.0 million. Settlement is scheduled for September 25, subject to customary closing conditions. Neither offering depends on the other closing.

Viking estimates net proceeds of approximately $258.2 million from the shares and approximately $218.0 million from the notes, before any underwriter options are exercised. The notes initially convert at 19.7044 shares per $1,000 of principal, equivalent to approximately $50.75 per share—a premium of approximately 45% to the stock offering price. Viking intends to use the proceeds for its VK2735 and VK3019 programs, other research and development, working capital and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
Rhea-AI Summary

Viking Therapeutics (VKTX) proposed separate stock and convertible-note offerings of $200.0 million each on September 23, 2026.

Both offerings are subject to market and other conditions, and neither depends on the other closing. Viking expects to grant separate 30-day underwriter options for up to an additional $30.0 million of stock and $30.0 million in notes. The senior unsecured notes mature on October 15, 2032, unless repurchased, redeemed or converted earlier. Their interest rate and initial conversion rate will be set at pricing.

Viking intends to use the net proceeds for VK2735 development and commercialization, VK3019 development, and other research and development, working capital and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags

FAQ

What is the current stock price of Viking Therapeutics (VKTX)?

Viking Therapeutics (VKTX) last closed at $24.77.

What is the market cap of Viking Therapeutics (VKTX)?

The market cap of Viking Therapeutics (VKTX) is approximately $3.2B.